The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, Masahiro Morise, Haruko Daga, Yasushi Goto, Toshiyuki Kozuki, Satoru Miura, Takaaki Sasaki, Akihiro Tamiya, Shunsuke Teraoka, Yukari Tsubata, Hiroshige Yoshioka, Yoshihiro Hattori, Chiyo Imamura, Yuki Katsuya, Reiko Matsui, Yuji Minegishi, Hidenori Mizugaki, Kaname NosakiYusuke Okuma, Setsuko Sakamoto, Takashi Sone, Kentaro Tanaka, Shigeki Umemura, Takeharu Yamanaka, Shinsuke Amano, Kazuo Hasegawa, Satoshi Morita, Kazuko Nakajima, Makoto Maemondo, Takashi Seto, Nobuyuki Yamamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50%, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.

Original languageEnglish
JournalInternational Journal of Clinical Oncology
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Guidelines
Japan
Patient Advocacy
Oncogenes
Pharmacists
Phosphotransferases
Nurses
Drug Therapy
Pharmaceutical Preparations
Therapeutics

Keywords

  • Chemotherapy
  • Guideline
  • Kinase inhibitor
  • Non-small cell lung cancer
  • Programed cell death-1 inhibitor
  • Programed death-ligand 1 inhibitor

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Cite this

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. / Akamatsu, Hiroaki; Ninomiya, Kiichiro; Kenmotsu, Hirotsugu; Morise, Masahiro; Daga, Haruko; Goto, Yasushi; Kozuki, Toshiyuki; Miura, Satoru; Sasaki, Takaaki; Tamiya, Akihiro; Teraoka, Shunsuke; Tsubata, Yukari; Yoshioka, Hiroshige; Hattori, Yoshihiro; Imamura, Chiyo; Katsuya, Yuki; Matsui, Reiko; Minegishi, Yuji; Mizugaki, Hidenori; Nosaki, Kaname; Okuma, Yusuke; Sakamoto, Setsuko; Sone, Takashi; Tanaka, Kentaro; Umemura, Shigeki; Yamanaka, Takeharu; Amano, Shinsuke; Hasegawa, Kazuo; Morita, Satoshi; Nakajima, Kazuko; Maemondo, Makoto; Seto, Takashi; Yamamoto, Nobuyuki.

In: International Journal of Clinical Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Akamatsu, H, Ninomiya, K, Kenmotsu, H, Morise, M, Daga, H, Goto, Y, Kozuki, T, Miura, S, Sasaki, T, Tamiya, A, Teraoka, S, Tsubata, Y, Yoshioka, H, Hattori, Y, Imamura, C, Katsuya, Y, Matsui, R, Minegishi, Y, Mizugaki, H, Nosaki, K, Okuma, Y, Sakamoto, S, Sone, T, Tanaka, K, Umemura, S, Yamanaka, T, Amano, S, Hasegawa, K, Morita, S, Nakajima, K, Maemondo, M, Seto, T & Yamamoto, N 2019, 'The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV', International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-019-01431-z
Akamatsu, Hiroaki ; Ninomiya, Kiichiro ; Kenmotsu, Hirotsugu ; Morise, Masahiro ; Daga, Haruko ; Goto, Yasushi ; Kozuki, Toshiyuki ; Miura, Satoru ; Sasaki, Takaaki ; Tamiya, Akihiro ; Teraoka, Shunsuke ; Tsubata, Yukari ; Yoshioka, Hiroshige ; Hattori, Yoshihiro ; Imamura, Chiyo ; Katsuya, Yuki ; Matsui, Reiko ; Minegishi, Yuji ; Mizugaki, Hidenori ; Nosaki, Kaname ; Okuma, Yusuke ; Sakamoto, Setsuko ; Sone, Takashi ; Tanaka, Kentaro ; Umemura, Shigeki ; Yamanaka, Takeharu ; Amano, Shinsuke ; Hasegawa, Kazuo ; Morita, Satoshi ; Nakajima, Kazuko ; Maemondo, Makoto ; Seto, Takashi ; Yamamoto, Nobuyuki. / The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. In: International Journal of Clinical Oncology. 2019.
@article{6905df66c5834e56b35f93ba8e9b25e5,
title = "The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV",
abstract = "According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50{\%}, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.",
keywords = "Chemotherapy, Guideline, Kinase inhibitor, Non-small cell lung cancer, Programed cell death-1 inhibitor, Programed death-ligand 1 inhibitor",
author = "Hiroaki Akamatsu and Kiichiro Ninomiya and Hirotsugu Kenmotsu and Masahiro Morise and Haruko Daga and Yasushi Goto and Toshiyuki Kozuki and Satoru Miura and Takaaki Sasaki and Akihiro Tamiya and Shunsuke Teraoka and Yukari Tsubata and Hiroshige Yoshioka and Yoshihiro Hattori and Chiyo Imamura and Yuki Katsuya and Reiko Matsui and Yuji Minegishi and Hidenori Mizugaki and Kaname Nosaki and Yusuke Okuma and Setsuko Sakamoto and Takashi Sone and Kentaro Tanaka and Shigeki Umemura and Takeharu Yamanaka and Shinsuke Amano and Kazuo Hasegawa and Satoshi Morita and Kazuko Nakajima and Makoto Maemondo and Takashi Seto and Nobuyuki Yamamoto",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10147-019-01431-z",
language = "English",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

AU - Akamatsu, Hiroaki

AU - Ninomiya, Kiichiro

AU - Kenmotsu, Hirotsugu

AU - Morise, Masahiro

AU - Daga, Haruko

AU - Goto, Yasushi

AU - Kozuki, Toshiyuki

AU - Miura, Satoru

AU - Sasaki, Takaaki

AU - Tamiya, Akihiro

AU - Teraoka, Shunsuke

AU - Tsubata, Yukari

AU - Yoshioka, Hiroshige

AU - Hattori, Yoshihiro

AU - Imamura, Chiyo

AU - Katsuya, Yuki

AU - Matsui, Reiko

AU - Minegishi, Yuji

AU - Mizugaki, Hidenori

AU - Nosaki, Kaname

AU - Okuma, Yusuke

AU - Sakamoto, Setsuko

AU - Sone, Takashi

AU - Tanaka, Kentaro

AU - Umemura, Shigeki

AU - Yamanaka, Takeharu

AU - Amano, Shinsuke

AU - Hasegawa, Kazuo

AU - Morita, Satoshi

AU - Nakajima, Kazuko

AU - Maemondo, Makoto

AU - Seto, Takashi

AU - Yamamoto, Nobuyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50%, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.

AB - According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50%, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.

KW - Chemotherapy

KW - Guideline

KW - Kinase inhibitor

KW - Non-small cell lung cancer

KW - Programed cell death-1 inhibitor

KW - Programed death-ligand 1 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85065403897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065403897&partnerID=8YFLogxK

U2 - 10.1007/s10147-019-01431-z

DO - 10.1007/s10147-019-01431-z

M3 - Article

AN - SCOPUS:85065403897

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -